Vistagen Therapeutics (MEX:VTGN) Cyclically Adjusted Book per Share: MXN255.41 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VTGN Vistagen Therapeutics Inc MEX:VTGN
16 GF Score
Price MXN10.65
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Cyclically Adjusted Book per Share?

Vistagen Therapeutics MEX:VTGN 16 Cyclically Adjusted Book per Share is MXN255.41 as of Jun. 2026. GuruFocus rates MEX:VTGN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Vistagen Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was MXN9.626. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN255.41 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Vistagen Therapeutics's average Cyclically Adjusted Book Growth Rate was 80.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Vistagen Therapeutics was 29.30% per year. The lowest was 1.70% per year. And the median was 9.75% per year.

As of today (2026-08-20), Vistagen Therapeutics's current stock price is MXN10.65. Vistagen Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was MXN255.41. Vistagen Therapeutics's Cyclically Adjusted PB Ratio of today is 0.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vistagen Therapeutics was 2.30. The lowest was 0.04. And the median was 0.66.


Vistagen Therapeutics  (MEX:VTGN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vistagen Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=10.65/255.41
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vistagen Therapeutics was 2.30. The lowest was 0.04. And the median was 0.66.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Vistagen Therapeutics Cyclically Adjusted Book per Share Related Terms


Vistagen Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Cyclically Adjusted Book per Share Chart

Vistagen Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 114.63

Vistagen Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 114.63 255.41

MEX:VTGN vs ASBP, CRIS, TOVX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Vistagen Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vistagen Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's Cyclically Adjusted PB Ratio falls into.


MEX:VTGN
16GF Score
Vistagen Therapeutics Inc MEX:VTGN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vistagen Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=9.626/333.9520*333.9520
=9.626

Current CPI (Jun. 2026) = 333.9520.

Vistagen Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 286.040 241.428 395.661
201612 186.346 241.432 257.756
201703 39.064 243.801 53.509
201706 -35.626 244.955 -48.570
201709 -78.392 246.819 -106.066
201712 267.571 246.524 362.463
201803 164.387 249.554 219.982
201806 82.226 251.989 108.971
201809 78.380 252.439 103.689
201812 32.011 251.233 42.551
201903 96.526 254.202 126.809
201906 21.926 256.143 28.586
201909 -50.487 256.759 -65.666
201912 -78.037 256.974 -101.413
202003 -81.968 258.115 -106.051
202006 -69.693 257.797 -90.281
202009 37.779 260.280 48.472
202012 403.715 260.474 517.600
202103 312.251 264.877 393.680
202106 266.992 271.696 328.170
202109 253.314 274.310 308.391
202112 238.331 278.802 285.475
202203 187.152 287.504 217.388
202206 134.447 296.311 151.526
202209 86.368 296.808 97.177
202212 58.443 296.797 65.759
202303 29.783 301.836 32.952
202306 14.910 305.109 16.319
202309 51.690 307.789 56.084
202312 77.435 306.746 84.303
202403 70.184 312.332 75.042
202406 70.967 314.175 75.434
202409 67.665 315.301 71.668
202412 59.747 315.605 63.220
202503 49.662 319.799 51.860
202506 36.502 322.561 37.791
202509 31.291 324.800 32.173
202512 23.141 324.054 23.848
202603 16.167 330.213 16.350
202606 9.626 333.952 9.626

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN255.41 mean?
Vistagen Therapeutics (MEX:VTGN) has a Cyclically Adjusted Book per Share of MXN255.41 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Vistagen Therapeutics and its competitors.
Is Vistagen Therapeutics' Cyclically Adjusted Book per Share too high?
Vistagen Therapeutics' current Cyclically Adjusted Book per Share is MXN255.41. Overall, Vistagen Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Cyclically Adjusted Book per Share compare to ASBP and CRIS?
Vistagen Therapeutics' Cyclically Adjusted Book per Share of MXN255.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current Cyclically Adjusted Book per Share is MXN255.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (MEX:VTGN) has a current Cyclically Adjusted Book per Share of MXN255.41. The current Cyclically Adjusted Book per Share is MXN255.41. Vistagen Therapeutics' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Vistagen Therapeutics (MEX:VTGN), the current Cyclically Adjusted Book per Share is MXN255.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vistagen Therapeutics Business Description

Other Exchanges VTGN:USA
Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
16GF Score

Get the complete analysis for MEX:VTGN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN10.65
Price